Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07430332

PHASE2

GLP-1 RA for Stage 1 Type 1 Diabetes

Sponsor: Children's Hospital Medical Center, Cincinnati

View on ClinicalTrials.gov

Summary

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

Official title: Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function

Key Details

Gender

All

Age Range

12 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2027-09-01

Completion Date

2030-01-01

Last Updated

2026-02-24

Healthy Volunteers

Yes

Conditions

Stage 1 Diabetes Mellitus, Type 1

Interventions

DRUG

Semaglutide

Study participants will be randomized to either placebo or semaglutide treatment for 12 months

DRUG

Placebo

Randomized to either placebo or semaglutide.

Locations (1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States